Search for: [Abstract = "P, p = 0.002\), and CDAI \(0.010\). In the subgroup continuing therapy with GP2013, the treatment effect was maintained for all analyzed disease activity scores, except PROs. For the total cohort, GP2013 drug survival was 80.0% after 1 year and 57.7% after 2 years of follow\-up, while in the subgroup undergone mandatory non\-medical switch, 84.1% after 1 year and 60.2% after 2 years which was significantly higher than in the subgroup treated with GP2013 “de novo” \(63.6% and 49.0% after 1 and 2 years of follow\-up, respectively\; p = 0.036\). In the total cohort and in patients continuing therapy with GP2013, the most common reason for discontinuation was remission \(38.6% and 40.3%, respectively\), followed by physician's decision \(27.1% and 27.4%, respectively\). In the second part of the study, among 114 PsA patients, 37.7% were using bDMARDs \(97.7% tumor necrosis factor inhibitor, TNFi and 2.3% interleukin\-12\/23 inhibitor, IL\-12\/23i, ustekinumab\). During the 5\-year follow\-up, the number of patients treated with bDMARDs increased from 37.7% to 46.5% and this was statistically significant \(p = 0.018\). After 5 years, 77.4% \(n = 41\) patients treated with bDMARDs were using TNFi, 18.9% \(n = 10\) interleukin\- 17A inhibitor \(interleukin\-17A inhibitor, IL\-17Ai, secukinumab\), 1.9% \(n = 1\) IL\-12\/23i \(ustekinumab\) and 1.9% \(n = 1\) RTX. At baseline, the highest remission rates were r"]
